148 related articles for article (PubMed ID: 1649476)
1. (-)-N,N'-but-2-ene-1,4-diylbimorphinans.
Schmidhammer H; Smith CF; Dalkner E; Erlach D; Heuberger M; Rollinger JM
Pharmazie; 1991 Feb; 46(2):101-2. PubMed ID: 1649476
[TBL] [Abstract][Full Text] [Related]
2. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 14-alkoxymorphinans, V: 6-Deoxyocyprodime, an opioid antagonist with decreased mu receptor selectivity in comparison to cyprodime.
Schmidhammer H; Jennewein HK; Smith CF
Arch Pharm (Weinheim); 1991 Apr; 324(4):209-11. PubMed ID: 1650547
[TBL] [Abstract][Full Text] [Related]
4. Cyprodime analogues: synthesis and pharmacological evaluation.
Schmidhammer H; Smith CF; Erlach D; Koch M; Krassnig R; Schwetz W; Wechner C
Prog Clin Biol Res; 1990; 328():37-40. PubMed ID: 2154795
[No Abstract] [Full Text] [Related]
5. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans.
Ananthan S; Kezar HS; Saini SK; Khare NK; Davis P; Dersch CM; Porreca F; Rothman RB
Bioorg Med Chem Lett; 2003 Feb; 13(3):529-32. PubMed ID: 12565965
[TBL] [Abstract][Full Text] [Related]
8. Comparison of dynorphin-selective Kappa receptors in mouse vas deferens and guinea pig ileum. Spare receptor fraction as a determinant of potency.
Cox BM; Chavkin C
Mol Pharmacol; 1983 Jan; 23(1):36-43. PubMed ID: 6135144
[No Abstract] [Full Text] [Related]
9. Diprenorphine has agonist activity at opioid kappa-receptors in the myenteric plexus of the guinea-pig ileum.
Traynor JR; Corbett AD; Kosterlitz HW
Eur J Pharmacol; 1987 May; 137(1):85-9. PubMed ID: 3038579
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the opioid activity of CAM and kappa agonists.
Furst S; Friedmann T; Kovacs A; Wagner T
NIDA Res Monogr; 1986; 75():224-7. PubMed ID: 2828975
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of a novel, non-competitive opioid receptor antagonist.
Davis P; Kramer T; Burks T
Proc West Pharmacol Soc; 1989; 32():163-6. PubMed ID: 2550940
[No Abstract] [Full Text] [Related]
12. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.
McLamore S; Ullrich T; Rothman RB; Xu H; Dersch C; Coop A; Davis P; Porreca F; Jacobson AE; Rice KC
J Med Chem; 2001 Apr; 44(9):1471-4. PubMed ID: 11311071
[TBL] [Abstract][Full Text] [Related]
13. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
[TBL] [Abstract][Full Text] [Related]
14. Agonist and antagonist opioid activity of axial and equatorial conformations of S-methyl- and S-allyl-morphinans.
Lemaire S; Belleau B; Jolicoeur FB
Eur J Pharmacol; 1994 Jun; 258(1-2):111-8. PubMed ID: 7925589
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of a casomorphin related pentapeptide, a competitive mu opioid receptor antagonist.
Davis P; Tourwe D; Delaet N; Kramer TH; Burks TF
Proc West Pharmacol Soc; 1991; 34():429-32. PubMed ID: 1664962
[No Abstract] [Full Text] [Related]
16. Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues.
James MK; Feldman PL; Schuster SV; Bilotta JM; Brackeen MF; Leighton HJ
J Pharmacol Exp Ther; 1991 Nov; 259(2):712-8. PubMed ID: 1658308
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and opioid activity of novel 6-substituted-6-demethoxy-ethenomorphinans.
Czakó B; Marton J; Berényi S; Gach K; Fichna J; Storr M; Tóth G; Sipos A; Janecka A
Bioorg Med Chem; 2010 May; 18(10):3535-42. PubMed ID: 20413312
[TBL] [Abstract][Full Text] [Related]
18. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
[TBL] [Abstract][Full Text] [Related]
19. Opioid profiles of Cys2-containing enkephalin analogues.
Pencheva N; Milanov P; Vezenkov L; Pajpanova T; Naydenova E
Eur J Pharmacol; 2004 Sep; 498(1-3):249-56. PubMed ID: 15364002
[TBL] [Abstract][Full Text] [Related]
20. The choice of opioid receptor subtype in isolated preparations by ohmefentanyl.
Jin WQ; Chen XJ; Chi ZQ
Sci Sin B; 1987 Feb; 30(2):176-81. PubMed ID: 3039656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
